融合生検の世界市場2020-2026:最終用途別(診断センター、病院、外来診療センター)、経路別、地域別

◆英語タイトル:Global Fusion Biopsy Market By End Use (Diagnostic centers, Hospitals and Ambulatory care centers), By Route (Transperineal and Transrectal), By Region, Industry Analysis and Forecast, 2020 - 2026
◆商品コード:KBV20OCT072
◆発行会社(リサーチ会社):KBV Research
◆発行日:2020年8月31日
◆ページ数:132
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ、カナダ、メキシコ、ロシア、ドイツ、英国、フランス、スペイン、イタリア、中国、日本、インド、韓国、シンガポール、オーストラリア、ブラジル、アルゼンチン、アラブ首長国連邦、サウジアラビア、南アフリカ、ナイジェリア
◆販売価格オプション(消費税別)
Single User(1名様利用)USD3,600 ⇒換算¥388,800見積依頼/購入/質問フォーム
Global License(法人利用)USD6,048 ⇒換算¥653,184見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKBV Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
KBV Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、融合生検の世界市場について、市場範囲・調査手法、市場概要、市場動向、最終用途別(診断センター、病院、外来診療センター)分析、経路別分析、地域別分析、企業概要などを総合的、多面的に調査・分析しました。
・市場範囲・調査手法
・市場概要
・市場動向
・融合生検の世界市場規模:最終用途別(診断センター、病院、外来診療センター)
・融合生検の世界市場規模:経路別
・融合生検の世界市場規模:地域別
・企業概要
【レポートの概要】

The Global Fusion Biopsy Market size is expected to reach $912.5 Million by 2026, rising at a market growth of 11.5% CAGR during the forecast period. Fusion biopsy is considered as the most reliable method of detection of prostate and breast cancer. It is difficult to visualize the entire prostrate even in the biopsy so there are many developments being done in fusion biopsy system such as trans-rectal ultra-guided prostate biopsy. The current biopsy system has less image resolution and chances biopsy needle can penetrate the tumor-free areas and it can be given negative results.

The second most common type of cancer in men is Prostate cancer. Each year more than 160,000 Americans are diagnosed with prostate cancer. For diagnosis and detection of prostate cancer, the primary diagnostic test includes Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) as they are more affordable and accessible. Though the PSA test is largely used for the detection of benign tumors that results in pointless invasive procedures and it also costs higher healthcare. Consequently, the rising demand for a more specific and sensitive screening method in prostate cancer is likely to boost the market growth for fusion biopsy.

The survival rate in the case of prostate cancer is more as compared to other types of cancer. But, the survival rate for prostate cancer has been less reported at the metastatic stage of cancer. To prevent prostate cancer from reaching up to a metastatic stage is highly needed, and for this purpose, either active surveillance or surgical intervention with other types of medication is required. There are many risks associated with surgical intervention such as erectile dysfunction, bleeding, urinary tract infection, and urinary incontinence. Thus, patients are usually seeking active surveillance and opting for regular biopsy, which in turn, is anticipated to drive the market growth of the MR/Ultrasound biopsy system.

Based on End Use, the market is segmented into Diagnostic centers, Hospitals and Ambulatory care centers. Based on Route, the market is segmented into Transperineal and Transrectal. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.

Strategies deployed in Fusion Biopsy Market

Nov-2018: Focal Healthcare received both FDA 510(k) clearance and Health Canada approval for its Fusion Bx 2.0 prostate biopsy solution. The Fusion Bx 2.0 is the second generation of Focal Healthcare’s prostate fusion biopsy device.
Sep-2016: UC-Care and AXELLA announced the Navigo and SmartBx Systems, new cutting edge vision for prostate MRI fusion biopsy. Navigo fuses previously captured prostate MRI images with live TRUS (transrectal ultrasound) images while the ultrasound transducer is inserted during the biopsy.
May-2016: Philips’ business Invivo partnered with SonaCare Medical to license Invivo’s UroNav fusion software with its Sonablate planning system. The partnership enabled clinicians to use the UroNav device to annotate and biopsy targeted prostate tissue and localizes the tissue appropriate for ablation directly with its Sonablate software.
Mar-2016: Eigen collaborated with Hitachi Medical Systems Europe. Under this collaboration, Hitachi was aimed to distribute the Artemis, Eigen’s robotic 3D targeted prostate biopsy device, through their subsidiaries’ sales network in Europe. Additionally, both companies expanded the versatility of Eigen’s Artemis and Hitachi Aloka’s suite of advanced ultrasound units, including their newest and most compact ultrasound unit yet, the Noblus.
Mar-2016: Hitachi signed an agreement with MedCom GmbH to distribute the latter company’s products through Hitachi’s subsidiaries sales network in Europe. BiopSee is the MedCom’s fusion imaging system for stereotactic, navigated, targeted prostate biopsy & therapy guidance. It is used in conjunction with Hitachi ultrasound systems. Hitachi is the sole distributor of the BiopSee products in this territory for Hitachi’s installed base and when bundled with Hitachi’s products.
Feb-2016: Focal Healthcare got 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its targeted prostate biopsy device, Fusion Bx. With the availability of Fusion Bx, clinicians can accurately take targeted biopsies directly from suspicious cancer regions within the prostate using MRI-ultrasound “fusion” technology.

Scope of the Study
Market Segmentation:

By End Use
• Diagnostic centers
• Hospitals
• Ambulatory care centers

By Route
• Transperineal
• Transrectal

By Geography
• North America
o US
o Canada
o Mexico
o Rest of North America
• Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Australia
o Rest of Asia Pacific
• LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA

Companies Profiled
• Koninklijke Philips N.V.
• Hitachi, Ltd.
• Baxter International, Inc. (MedCom)
• Esaote SpA
• Eigen
• KOELIS, Inc.
• Focal Healthcare, Inc.
• UC-Care Medical Systems Ltd.

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Fusion Biopsy Market, by End Use
1.4.2 Global Fusion Biopsy Market, by Route
1.4.3 Global Fusion Biopsy Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent market developments in Fusion Biopsy Market
Chapter 4. Global Fusion Biopsy Market by End Use
4.1 Global Diagnostic centers Market by Region
4.2 Global Hospitals Market by Region
4.3 Global Ambulatory care centers Market by Region
Chapter 5. Global Fusion Biopsy Market by Route
5.1 Global Transperineal Market by Region
5.2 Global Transrectal Market by Region
Chapter 6. Global Fusion Biopsy Market by Region
6.1 North America Fusion Biopsy Market
6.1.1 North America Fusion Biopsy Market by End Uses
6.1.1.1 North America Diagnostic centers Market by Country
6.1.1.2 North America Hospitals Market by Country
6.1.1.3 North America Ambulatory care centers Market by Country
6.1.2 North America Fusion Biopsy Market by Route
6.1.2.1 North America Transperineal Market by Country
6.1.2.2 North America Transrectal Market by Country
6.1.3 North America Fusion Biopsy Market by Country
6.1.3.1 USA Fusion Biopsy Market
6.1.3.1.1 USA Fusion Biopsy Market by End Uses
6.1.3.1.2 USA Fusion Biopsy Market by Route
6.1.3.2 Canada Fusion Biopsy Market
6.1.3.2.1 Canada Fusion Biopsy Market by End Users
6.1.3.2.2 Canada Fusion Biopsy Market by Route
6.1.3.3 Mexico Fusion Biopsy Market
6.1.3.3.1 Mexico Fusion Biopsy Market by End Users
6.1.3.3.2 Mexico Fusion Biopsy Market by Route
6.1.3.4 Rest of North America Fusion Biopsy Market
6.1.3.4.1 Rest of North America Fusion Biopsy Market by End Users
6.1.3.4.2 Rest of North America Fusion Biopsy Market by Route
6.2 Europe Fusion Biopsy Market
6.2.1 Europe Fusion Biopsy Market by End Uses
6.2.1.1 Europe Diagnostic centers Market by Country
6.2.1.2 Europe Hospitals Market by Country
6.2.1.3 Europe Ambulatory care centers Market by Country
6.2.2 Europe Fusion Biopsy Market by Route
6.2.2.1 Europe Transperineal Market by Country
6.2.2.2 Europe Transrectal Market by Country
6.2.3 Europe Fusion Biopsy Market by Country
6.2.3.1 Germany Fusion Biopsy Market
6.2.3.1.1 Germany Fusion Biopsy Market by End Uses
6.2.3.1.2 Germany Fusion Biopsy Market by Route
6.2.3.2 UK Fusion Biopsy Market
6.2.3.2.1 UK Fusion Biopsy Market by End Uses
6.2.3.2.2 UK Fusion Biopsy Market by Route
6.2.3.3 France Fusion Biopsy Market
6.2.3.3.1 France Fusion Biopsy Market by End Uses
6.2.3.3.2 France Fusion Biopsy Market by Route
6.2.3.4 Russia Fusion Biopsy Market
6.2.3.4.1 Russia Fusion Biopsy Market by End Uses
6.2.3.4.2 Russia Fusion Biopsy Market by Route
6.2.3.5 Spain Fusion Biopsy Market
6.2.3.5.1 Spain Fusion Biopsy Market by End Uses
6.2.3.5.2 Spain Fusion Biopsy Market by Route
6.2.3.6 Italy Fusion Biopsy Market
6.2.3.6.1 Italy Fusion Biopsy Market by End Uses
6.2.3.6.2 Italy Fusion Biopsy Market by Route
6.2.3.7 Rest of Europe Fusion Biopsy Market
6.2.3.7.1 Rest of Europe Fusion Biopsy Market by End Uses
6.2.3.7.2 Rest of Europe Fusion Biopsy Market by Route
6.3 Asia Pacific Fusion Biopsy Market
6.3.1 Asia Pacific Fusion Biopsy Market by End Uses
6.3.1.1 Asia Pacific Diagnostic centers Market by Country
6.3.1.2 Asia Pacific Hospitals Market by Country
6.3.1.3 Asia Pacific Ambulatory care centers Market by Country
6.3.2 Asia Pacific Fusion Biopsy Market by Route
6.3.2.1 Asia Pacific Transperineal Market by Country
6.3.2.2 Asia Pacific Transrectal Market by Country
6.3.3 Asia Pacific Fusion Biopsy Market by Country
6.3.3.1 China Fusion Biopsy Market
6.3.3.1.1 China Fusion Biopsy Market by End Uses
6.3.3.1.2 China Fusion Biopsy Market by Route
6.3.3.2 India Fusion Biopsy Market
6.3.3.2.1 India Fusion Biopsy Market by End Uses
6.3.3.2.2 India Fusion Biopsy Market by Route
6.3.3.3 Japan Fusion Biopsy Market
6.3.3.3.1 Japan Fusion Biopsy Market by End Uses
6.3.3.3.2 Japan Fusion Biopsy Market by Route
6.3.3.4 Australia Fusion Biopsy Market
6.3.3.4.1 Australia Fusion Biopsy Market by End Uses
6.3.3.4.2 Australia Fusion Biopsy Market by Route
6.3.3.5 South Korea Fusion Biopsy Market
6.3.3.5.1 South Korea Fusion Biopsy Market by End Uses
6.3.3.5.2 South Korea Fusion Biopsy Market by Route
6.3.3.6 Singapore Fusion Biopsy Market
6.3.3.6.1 Singapore Fusion Biopsy Market by End Uses
6.3.3.6.2 Singapore Fusion Biopsy Market by Route
6.3.3.7 Rest of Asia Pacific Fusion Biopsy Market
6.3.3.7.1 Rest of Asia Pacific Fusion Biopsy Market by End Uses
6.3.3.7.2 Rest of Asia Pacific Fusion Biopsy Market by Route
6.4 LAMEA Fusion Biopsy Market
6.4.1 LAMEA Fusion Biopsy Market by End Uses
6.4.1.1 LAMEA Diagnostic centers Market by Country
6.4.1.2 LAMEA Hospitals Market by Country
6.4.1.3 LAMEA Ambulatory care centers Market by Country
6.4.2 LAMEA Fusion Biopsy Market by Route
6.4.2.1 LAMEA Transperineal Market by Country
6.4.2.2 LAMEA Transrectal Market by Country
6.4.3 LAMEA Fusion Biopsy Market by Country
6.4.3.1 Brazil Fusion Biopsy Market
6.4.3.1.1 Brazil Fusion Biopsy Market by End Uses
6.4.3.1.2 Brazil Fusion Biopsy Market by Route
6.4.3.2 Argentina Fusion Biopsy Market
6.4.3.2.1 Argentina Fusion Biopsy Market by End Uses
6.4.3.2.2 Argentina Fusion Biopsy Market by Route
6.4.3.3 UAE Fusion Biopsy Market
6.4.3.3.1 UAE Fusion Biopsy Market by End Uses
6.4.3.3.2 UAE Fusion Biopsy Market by Route
6.4.3.4 Saudi Arabia Fusion Biopsy Market
6.4.3.4.1 Saudi Arabia Fusion Biopsy Market by End Uses
6.4.3.4.2 Saudi Arabia Fusion Biopsy Market by Route
6.4.3.5 South Africa Fusion Biopsy Market
6.4.3.5.1 South Africa Fusion Biopsy Market by End Uses
6.4.3.5.2 South Africa Fusion Biopsy Market by Route
6.4.3.6 Nigeria Fusion Biopsy Market
6.4.3.6.1 Nigeria Fusion Biopsy Market by End Uses
6.4.3.6.2 Nigeria Fusion Biopsy Market by Route
6.4.3.7 Rest of LAMEA Fusion Biopsy Market
6.4.3.7.1 Rest of LAMEA Fusion Biopsy Market by End Uses
6.4.3.7.2 Rest of LAMEA Fusion Biopsy Market by Route
Chapter 7. Company Profiles
7.1 Koninklijke Philips N.V.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.2 Hitachi, Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Baxter International, Inc. (MedCom)
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.4 Esaote SpA
7.4.1 Company Overview
7.5 Eigen
7.5.1 Company Overview
7.5.2 Recent strategies and developments:
7.5.2.1 Partnerships, Collaborations, and Agreements:
7.6 KOELIS, Inc.
7.6.1 Company Overview
7.7 Focal Healthcare, Inc.
7.7.1 Company Overview
7.7.2 Recent strategies and developments:
7.7.2.1 Approvals:
7.8 UC-Care Medical Systems Ltd.
7.8.1 Company Overview
7.8.2 Recent strategies and developments:
7.8.2.1 Partnerships, Collaborations, and Agreements:



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[融合生検の世界市場2020-2026:最終用途別(診断センター、病院、外来診療センター)、経路別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆